Context: Halozyme Therapeutics, a San Diego company best known for licensing its ENHANZE technology for subcutaneous drug delivery, which first Merck in the District of New Jersey on April 24, 2025,and is enforcing a separate family of MDASE patents against Merck’s subcutaneous version of Keytruda. The product is sold as Keytruda SC in Europe and as Keytruda Qlex in the U.S. Halozyme previously won a preliminary injunction against it in Germany (December 6, 2025 ip fray article). Keytruda, Merck’s cancer immunotherapy, generated $31.7 billion in sales in 2025, counting the intravenous and subcutaneous versions together (February 3, 2026, Merck, press release).
To Read The Full Story
Continue reading your article with a Membership
Counsel
In the Netherlands
Halozyme is being represented by Brinkhof’s Mark van Gardingen, Rien Broekstra, Barbara Mooij, Charlotte Tiems, Eveline Lots, and Atze van Stralen.
Meanwhile, Merck is being represented by Hogan Lovells Cadwalader’s Gertjan Kuipers, Dirk-Jan Ridderinkhof, Miriam Gundt, and Andreas von Falck.
In Germany, the UK, and the U.S.
Halozyme is being represented by Quinn Emanuel’s Marcus Grosch, David Lancaster, David Nelson, and Zach Summers.
Merck is being represented by Hogan Lovells Cadwalader’s Stephen Bennett, Helen Poulson, and Katie Barton.
In the U.S., Merck is being represented by Sidley Austin’s Jeff Kushan.